Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes

NCT03018028 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT03018028
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03018028 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Completed
Start date
January 10, 2017
Completion date
August 15, 2018
Enrollment
243 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 2